Once-Weekly Semaglutide in Adults with Overweight or Obesity
Source: View publication →
In adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide 2.4 mg, combined with a lifestyle intervention, produced substantial and sustained weight loss compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The STEP 1 trial marked a paradigm shift in obesity pharmacotherapy. By demonstrating that a weekly GLP-1 receptor agonist could achieve a mean weight loss of nearly 15%—a magnitude historically only attainable via bariatric surgery or highly intensive regimens—it established high-dose semaglutide as a highly effective therapy. This pivotal trial led directly to the FDA approval of semaglutide 2.4 mg (Wegovy) for chronic weight management.
Historical Context
Prior to this trial, pharmacological treatments for obesity typically yielded modest weight loss (usually 5-9%) and were often hampered by systemic, cardiovascular, or psychiatric side effects. Liraglutide, an earlier daily GLP-1 receptor agonist approved for weight management in 2014, achieved an average weight loss of approximately 8%. Semaglutide was initially approved for type 2 diabetes at lower doses; its evaluation at 2.4 mg weekly in the STEP clinical program successfully bridged the historical efficacy gap between medical therapy and surgical interventions.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of semaglutide, a GLP-1 receptor agonist, promote weight loss in patients without diabetes, and why are gastrointestinal side effects the most common adverse events?
Key Response
Semaglutide acts centrally on the hypothalamus to decrease appetite and increase satiety, and peripherally delays gastric emptying. The delayed gastric emptying combined with central activation of nausea pathways explains the prominent gastrointestinal side effects (nausea, vomiting, diarrhea), which is crucial for understanding the basic pharmacology and pathophysiology of the drug.
A 35-year-old patient with a BMI of 34 kg/m2 starts semaglutide 2.4 mg for weight management but experiences significant nausea and vomiting during the up-titration phase. What is the appropriate clinical management strategy to ensure medication adherence while mitigating these side effects?
Key Response
Residents must know how to manage GLP-1 RA titration. Strategies include holding the dose escalation, reverting to the previously tolerated dose, advising on smaller and more frequent meals, avoiding high-fat or spicy foods, and occasionally using short-term antiemetics. Knowing when to pause titration versus when to discontinue is key to successful obesity management.
The STEP 1 trial demonstrated an impressive mean weight loss of nearly 15%. However, considering the composition of weight lost (fat mass versus fat-free mass) with high-dose GLP-1 RAs, what are the potential long-term risks regarding sarcopenic obesity, and how should this influence the prescription of concurrent resistance training?
Key Response
Fellows in endocrinology or obesity medicine must look beyond the scale. Rapid weight loss with incretins can lead to a disproportionate loss of lean body mass. If a patient later regains weight (often as fat), their metabolic rate and functional status decline. Thus, combining GLP-1 RAs with targeted resistance training and adequate protein intake is a critical advanced management nuance.
STEP 1 positions semaglutide as a highly effective intervention for obesity, but subsequent extension data shows significant weight regain upon cessation. How does this paradigm shift obesity management from a model of acute intervention to chronic disease management, and how should you counsel patients regarding the likely need for lifelong therapy?
Key Response
Attendings must contextualize trials into long-term practice. Viewing obesity as a chronic, relapsing disease like hypertension or asthma changes the treatment paradigm. Counseling patients upfront that GLP-1 RA therapy may need to be indefinite to maintain weight loss sets realistic expectations and addresses the physiological counter-regulation to weight loss.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The STEP 1 trial utilized both a treatment policy estimand (regardless of adherence) and a trial product estimand (assuming adherence). How do these dual statistical approaches impact the interpretation of the drug's efficacy, and what are the limitations of the multiple imputation methods used for missing data due to high dropout rates from GI adverse events?
Key Response
A PhD level critique focuses on the estimand framework (ICH E9 R1). The treatment policy estimand provides a real-world effectiveness view (intention-to-treat equivalent), while the trial product estimand shows maximal biological efficacy. High dropout due to tolerability issues can bias these estimates depending on whether missing-not-at-random (MNAR) or missing-at-random (MAR) assumptions are used during imputation.
The trial protocol included a 500 kcal/day deficit and 150 minutes of exercise weekly for both groups. As an editor reviewing this manuscript, how do you critically evaluate whether the unequal adherence to this lifestyle intervention between the semaglutide and placebo groups confounds the true pharmacological effect size reported in the study?
Key Response
A critical reviewer would flag that drug-induced satiety makes adherence to a caloric deficit much easier. The placebo group's meager 2.4% weight loss suggests low adherence to the intensive lifestyle intervention on their own. Therefore, the 14.9% weight loss in the treatment group is not purely pharmacological but a synergistic effect of the drug enabling the lifestyle change, which is a vital distinction for editorial framing.
Given the unprecedented 14.9% weight loss observed in STEP 1, which approaches the efficacy of some bariatric procedures, how should current clinical practice guidelines (such as the AHA/ACC/TOS guidelines for the management of overweight and obesity) be updated regarding the sequencing of pharmacotherapy versus metabolic surgery for patients with class II or III obesity?
Key Response
Current guidelines often position pharmacotherapy as an adjunct for BMI > 30 and surgery for BMI > 40 (or > 35 with comorbidities). The magnitude of effect from semaglutide 2.4 mg blurs these lines, necessitating a potential guideline update to recommend high-efficacy GLP-1 RAs as a standardized step-therapy or primary alternative before considering invasive metabolic surgery, altering the strength of recommendation for immediate surgical referral.
Clinical Landscape
Noteworthy Related Trials
SCALE Obesity and Prediabetes Trial
Tested
Liraglutide 3.0 mg daily
Population
Adults with BMI >= 30, or >= 27 with complications (without T2DM)
Comparator
Placebo
Endpoint
Change in body weight and proportion losing >= 5% or >= 10% weight at week 56
SURMOUNT-1 Trial
Tested
Tirzepatide 5 mg, 10 mg, or 15 mg weekly
Population
Adults with BMI >= 30, or >= 27 with >= 1 complication (without diabetes)
Comparator
Placebo
Endpoint
Percentage change in weight from baseline and weight reduction of >= 5% at 72 weeks
SELECT Trial
Tested
Semaglutide 2.4 mg weekly
Population
Adults >= 45 years with preexisting CVD and BMI >= 27 (without diabetes)
Comparator
Placebo
Endpoint
Composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis